Is NGNE or CRBP more profitable?

Neurogene's return on equity of -45.10% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -45.10% -41.00% Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media refer more to NGNE or CRBP?

In the previous week, Neurogene and Neurogene both had 2 articles in the media. Neurogene's average media sentiment score of 1.58 beat Corbus Pharmaceuticals' score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corbus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTMX or CRBP?

In the previous week, CytomX Therapeutics had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for CytomX Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CRBP or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is CRBP or AVTE more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -87.05% -74.22% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media refer more to RGNX or CRBP?

In the previous week, REGENXBIO had 18 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 20 mentions for REGENXBIO and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.00 beat REGENXBIO's score of -0.11 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, BBOT or CRBP?

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A

Is BBOT or CRBP more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BridgeBio Oncology Therapeutics N/A -46.90% -42.17% Corbus Pharmaceuticals N/A -87.05% -74.22%

Corbus Pharmaceuticals (CRBP) Competitors

$11.31 +0.62 (+5.80%)

Closing price 04:00 PM Eastern

Extended Trading

$11.22 -0.09 (-0.80%)

As of 05:28 PM Eastern

Compare

CRBP vs. NGNE, CTMX, AVTE, RGNX, and BBOT

Should you buy Corbus Pharmaceuticals stock or one of its competitors? Corbus Pharmaceuticals's main competitors and comparable companies include Neurogene (NGNE), CytomX Therapeutics (CTMX), Aerovate Therapeutics (AVTE), REGENXBIO (RGNX), and BridgeBio Oncology Therapeutics (BBOT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corbus Pharmaceuticals compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurogene's return on equity of -45.10% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

In the previous week, Neurogene and Neurogene both had 2 articles in the media. Neurogene's average media sentiment score of 1.58 beat Corbus Pharmaceuticals' score of 0.00 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene presently has a consensus price target of $83.67, indicating a potential upside of 104.86%. Corbus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 262.51%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	878.72	-$90.35M	-$5.03	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Summary

Neurogene beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, CytomX Therapeutics had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for CytomX Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.64	-$17.37M	-$0.50	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CytomX Therapeutics presently has a consensus price target of $11.90, indicating a potential upside of 253.12%. Corbus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 262.51%. Given Corbus Pharmaceuticals' higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Summary

CytomX Therapeutics beats Corbus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Corbus Pharmaceuticals has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Corbus Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 262.51%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Corbus Pharmaceuticals' return on equity of -87.05% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Corbus Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Corbus Pharmaceuticals' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Aerovate Therapeutics	Neutral

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Corbus Pharmaceuticals beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Corbus Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.45	-$193.88M	-$3.79	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

In the previous week, REGENXBIO had 18 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 20 mentions for REGENXBIO and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.00 beat REGENXBIO's score of -0.11 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Corbus Pharmaceuticals' return on equity of -87.05% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

REGENXBIO currently has a consensus target price of $23.27, indicating a potential upside of 161.20%. Corbus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 262.51%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

REGENXBIO has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, meaning that its stock price is 159% more volatile than the broader market.

Summary

REGENXBIO beats Corbus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.40, indicating a potential upside of 160.41%. Corbus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 262.51%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for BridgeBio Oncology Therapeutics and 2 mentions for Corbus Pharmaceuticals. BridgeBio Oncology Therapeutics' average media sentiment score of 0.67 beat Corbus Pharmaceuticals' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Oncology Therapeutics beats Corbus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$199.60M	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-1.83	11.81	270.94	24.14
Price / Sales	N/A	1,381.12	634.77	96.69
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	2.06	16.86	13.14	6.25
Net Income	-$78.54M	-$22.76M	$3.46B	$347.86M
7 Day Performance	12.20%	4.71%	3.23%	1.57%
1 Month Performance	23.34%	12.26%	8.82%	5.24%
1 Year Performance	14.36%	60.84%	27.70%	17.87%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	2.8583 of 5 stars	$11.31 +5.8%	$41.00 +262.5%	+9.2%	$199.60M	N/A	N/A	40	High Trading Volume
NGNE Neurogene	2.5403 of 5 stars	$36.27 -1.1%	$83.67 +130.7%	+98.3%	$725.76M	$930K	N/A	90	Positive News
CTMX CytomX Therapeutics	2.2822 of 5 stars	$3.33 -3.6%	$11.90 +257.9%	+55.2%	$724.52M	$76.20M	N/A	170	Analyst Downgrade
AVTE Aerovate Therapeutics	N/A	$24.71 +3.8%	N/A	+159.3%	$716.22M	N/A	N/A	20	High Trading Volume
RGNX REGENXBIO	2.888 of 5 stars	$10.83 -4.4%	$23.73 +119.0%	-10.5%	$714.95M	$170.44M	N/A	370	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. NGNE, CTMX, AVTE, RGNX, and BBOT

How does Corbus Pharmaceuticals compare to Neurogene?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to REGENXBIO?

Summary

How does Corbus Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. NGNE, CTMX, AVTE, RGNX, and BBOT

How does Corbus Pharmaceuticals compare to Neurogene?

Which has more volatility & risk, NGNE or CRBP?

Do institutionals and insiders believe in NGNE or CRBP?

Is NGNE or CRBP more profitable?

Does the media refer more to NGNE or CRBP?

Do analysts rate NGNE or CRBP?

Which has preferable valuation and earnings, NGNE or CRBP?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Does the media prefer CTMX or CRBP?

Which has more risk & volatility, CTMX or CRBP?

Which has higher valuation & earnings, CTMX or CRBP?

Do insiders & institutionals believe in CTMX or CRBP?

Do analysts rate CTMX or CRBP?

Is CTMX or CRBP more profitable?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Which has stronger earnings and valuation, CRBP or AVTE?

Which has more risk and volatility, CRBP or AVTE?

Do analysts prefer CRBP or AVTE?

Is CRBP or AVTE more profitable?

Does the media prefer CRBP or AVTE?

Do institutionals and insiders believe in CRBP or AVTE?

Summary

How does Corbus Pharmaceuticals compare to REGENXBIO?

Which has better earnings & valuation, RGNX or CRBP?

Does the media refer more to RGNX or CRBP?

Is RGNX or CRBP more profitable?

Do analysts recommend RGNX or CRBP?

Do insiders & institutionals have more ownership in RGNX or CRBP?

Which has more risk and volatility, RGNX or CRBP?

Summary

How does Corbus Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Is BBOT or CRBP more profitable?

Which has better valuation & earnings, BBOT or CRBP?

Which has more risk and volatility, BBOT or CRBP?

Do insiders & institutionals believe in BBOT or CRBP?

Do analysts prefer BBOT or CRBP?

Does the media refer more to BBOT or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools